For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

A POC Clinical Trial for PTSD with a First­-in-­Class Vasopressin 1a Receptor Antagonist

Participants: 

This study is no longer recruiting.

Purpose: 

This study was a clinical trial which tested an experimental drug for the treatment of Post-Traumatic Stress Disorder (PTSD).

The population recruited were individuals who have served in the Iraq or Afghanistan wars and were experiencing any difficulties related to a mild or moderate traumatic brain injury (TBI) sustained during deployment.

Details: 

Following the initial screening phase, participants received the medication treatment for 8 weeks and the placebo for 8 weeks. This study lasted a total of 18 weeks. Participants were assessed at baseline and then every 2 weeks until the end of the study. Participants were compensated for all completed assessments (up to a total of $400).

 


Study Flyer

Manhattan Offices

425 East 61st Street
New York, NY 10065

435 East 70th Street
New York, NY 10021

Westchester Office

21 Bloomingdale Road
White Plains, NY 10605